Tagged with Strategy

Korea Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans.   We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug Dr Cho, could you start by…

USA Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the challenges of being a biotech entrepreneur.   From my experience, many great ideas actually come from people unconstrained by the…

China The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly has struck a deal for the exclusive license of Innovent’s TYVYT® drug outside of China stands to catapult the Chinese…

China Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from the crowd in China. He also touches on commercialization, partnerships, funding, and the evolution of the Chinese biopharma landscape.  …

USA Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture.   We…

USA PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health of society, and how Lundbeck is well-positioned to address this in North America.   As the global pandemic rages on,…

China The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment in 2017 at a pace that would seem to outpace the fast-moving China biotech industry.   [Post-merger], I-Mab became an…

Belgium Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and a global pandemic. de Bisschop also touches on key product launches in both oncology and dermatology, the synergies between these…

USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic.  …

Belgium Kevin Houdenaert, general manager for Benelux and the Nordics at Italian rare disease, specialty and primary care specialist Recordati, gives an overview of the market access specificities of the markets he manages, the autonomy that Recordati country managers enjoy, and his main priorities for 2020.   I see a lot…

Sanofi Sanofi’s inflammation drug Dupixent® is driving a substantial percentage of the firm’s sales in 2020, reaching USD 1.92 billion in the first half of the year, with a reported growth of 94 percent. Sanofi Genzyme Executive VP Bill Sibold recently spoke exclusively to PharmaBoardroom about the drug’s success.   Dupixent®…

Sanofi With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on June 15th 2020.    Under the watch of CEO Paul Hudson, appointed at the end of 2019, Sanofi has initiated…